Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-06
2006-06-06
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S274000, C514S300000, C514S352000, C540S580000, C544S316000, C544S335000, C546S122000, C546S311000, C546S312000
Reexamination Certificate
active
07056909
ABSTRACT:
The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
REFERENCES:
patent: 6048861 (2000-04-01), Askew et al.
Miller et al., Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic, Journal of Medicinal Chemistry, vol. 43, No. 1, pp. 22-26, Jan. 13, 2000.
Coleman Brenda
Daniel Mark R.
Merck & Co. , Inc.
Shatynski Patricia A.
LandOfFree
Alpha v integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha v integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha v integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3706886